MedTrace Logo

CAN BREATHE in COPD Trial

NCT03060993 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-02-23

No results posted yet for this study

Summary

A growing body of physiological evidence now exists to support a potential role for inhaled cannabis in the medical management of adults with chronic obstructive pulmonary disease (COPD), particularly as it may related to improving pulmonary function, alleviating the symptom of breathlessness and improving exercise endurance. The purpose of this randomized double-blind crossover trials is to evaluate the efficacy and physiological mechanism(s) of action of inhaled vaporized cannabis targeted to relief of physical activity-related breathlessness and exercise endurance in symptomatic patients with severe-to-very severe COPD.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Breathlessness
  • Exercise Intolerance

Interventions

DRUG

Cannabis

Patients will be administered cannabis (THC/CBD) in vaporized form.

DRUG

Placebo

Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.

Sponsors & Collaborators

Principal Investigators

  • Dennis Jensen, Ph.D. · McGill University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2018-01-01
Completion
2018-04-30
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03060993 on ClinicalTrials.gov